[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
Article
January 9, 1995

Combination Products as First-Line Pharmacotherapy

Author Affiliations

Rockville, Md

Arch Intern Med. 1995;155(1):117. doi:10.1001/archinte.1995.00430010125024
Abstract

Our editorial1 in the July 11, 1994, issue of the Archives stated that betaxolol-chlorthalidone and bisoprolol-hydrochlorothiazide are the only fixed-dose combination products approved in the United States as first-line pharmacotherapy for hypertension. This is incorrect.

We inadvertently neglected to discuss the fixed-dose combination of captopril and hydrochlorothiazide. This combination was approved in 1984, and it was approved as first-line therapy in 1991. The latter approval was a consequence of the marked improvement in the regimen that the combination allows, ie, the combination can be effectively administered once a day, while captopril monotherapy must be given twice or three times a day. The approval of captopril-hydrochlorothiazide as first-line therapy was, thus, an exception to the generalization overbroadly stated in our editorial that no combination of an angiotensin-converting enzyme inhibitor and hydrochlorothiazide could ever be approved as first-line therapy. Captopril-hydrochlorothiazide was approved—and similar decisions might be made in the future—because the

×